Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

3 Stocks Ready to Skyrocket With a Potential 100%+ Earnings Surge in 2024

Published 12/14/2023, 05:43 AM
  • A company's earnings performance is a crucial factor influencing stock prices over the long-term.
  • The market is anticipating several companies' earnings per share (EPS) to increase by more than 100% in 2024.
  • Let's explore three such stocks poised for a significant earnings surge next year.
  • History shows that significant drops in Treasury bond yields are favorable for the stock market. Since 1980, there have been 33 instances where the yields on 10-Year Treasury bonds fell by 50 basis points or more in a month.

    The average three-month return for the S&P 500 following such occurrences was nearly +8%, and for the Russell 2000, it was +8.2%. This suggests that the stock market is likely to continue its upward trend as we enter 2024.

    Meanwhile, over 60% of stocks listed on the S&P 500 hit a new 20-day high last week. Since 1972, this has happened 15 other times, and the index surged one year later on 100% of those occasions, generating an average return of +18%.

    In light of these noteworthy facts, FactSet has identified some stocks that are set to ride this potential bull market and experience a 100% surge in earnings next year.

    Understanding that these are projections and may not materialize, let's take a look at three top companies set to see their earnings skyrocket.

    1. Merck

    Merck & Company Inc (NYSE:MRK) is the oldest pharmaceutical and chemical company in the world, having been founded in 1668.

    With more than 57,000 employees in more than 60 countries worldwide, Merck is considered one of the largest pharmaceutical companies in the world.

    Merck Daily Chart

    It pays a dividend of $0.77 on January 8, and to receive it, shares must be held before December 14. The dividend yield is +2.95%.

    On February 1, it presents its quarterly results. By 2024 it expects revenue growth of 5.3% and earnings per share (EPS) of 513%, i.e., to earn $8.44 per share in 2024.

    Its shares are up +1.85% in the last month. The market consensus sees potential at $123.30 in 12 months.

    2. Stanley Black & Decker

    Stanley Black & Decker (NYSE:SWK) is a manufacturer and distributor of products for do-it-yourself and gardening, as well as for commercial applications.

    It was born as a result of the 1920 merger of Stanley's Bolt Manufactory and Stanley Rule and Level Company.

    Stanley Black and Deckner Stock Price Chart

    Its dividend yield is +3.50%.

    On January 25 it presents its quarterly accounts. By 2024 it expects revenue growth of 2.3% and earnings per share (EPS) of 250%.

    Its shares are up +16.10% for the year and +7% in the last three months. It has 17 ratings, of which 3 are buy, 13 are hold and 1 is sell. The market estimates a 12-month potential at $105.16.

    3. Pfizer

    Pfizer (NYSE:PFE) is an American pharmaceutical company that, after several mergers carried out with Pharmacia Upjohn and Parke Davis, is the world's leading laboratory in the pharmaceutical sector.

    The company is headquartered in New York and was founded in 1849. Its dividend yield is +5.74%.

    Pfizer Price Chart

    On January 30, it will present its quarterly accounts. For 2024 it is expected to increase revenues by 6.8% and earnings per share (EPS) by 102% to $3.16 per share.

    It has not had a good year, but the market estimates its potential at $40-42.


    You can easily determine whether a company is suitable for your risk profile by conducting a detailed fundamental analysis on InvestingPro according to your criteria. This way, you will get highly professional help in shaping your portfolio.

    In addition, you can sign up for InvestingPro, one of the most comprehensive platforms in the market for portfolio management and fundamental analysis, much cheaper with the biggest discount of the year (up to 60%), by taking advantage of our extended Cyber Monday deal.

    Claim Your Discount Today!

    Disclaimer: This article is written for informational purposes only; it does not constitute a solicitation, offer, advice, or recommendation to invest as such it is not intended to incentivize the purchase of assets in any way. I would like to remind you that any type of asset, is evaluated from multiple points of view and is highly risky therefore, any investment decision and the associated risk remains with the investor.

3rd party Ad. Not an offer or recommendation by See disclosure here or remove ads .

Latest comments

All companies anticipate the rise of their own ego, I mean earnings. However narrative catalysts are more reliable. What stocks will boon with all the pending news of war
Contrary to what the article says, Pfizer had a very bad year in 2023.
The market is correct in its 2023 valuation of PFE coming off Covid and slower take up of shots and Paxlovid. PFE has had a lousy 23 because they need to pivot to something new which they do not have on the horizon. Hence 24 will be sideways. At best it is a major long term hold that will need to cut its dividend in the future as well. The valuation may be a bit oversold today but again…..its gonna be sideways!!
Rarely does bear switch to bull. Usually a sideways snake first
Perma bull is not objective analyst .
Completely trash article. No real distinguishing economic factors to justify your stock picks.
You should have explained Merck, it seems so random to 100%, are you predicting some sort of pandemic sir?
You cra cra Mr Cruz
Pfizer- NO THX
BUT. They are not going out of business and buy when there is blood in the streets. It may take a while and good dividend.
infy and wipro
Lol hard pass
PFE?? Terrible stock to consider
Black and decker wanished from the nordic countrys becouse of its totaly lack of quality in the gear
Read my reply to Ed K.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.